Abstract

Purpose

To assess the capability of ultrasound-computed tomography (US-CT) fusion imaging to guide a precise targeting of renal tumors invisible or poorly visible with US

Materials and methods

From 2016 renal tumors poorly visible or inconspicuous/invisible at US were treated at our institution with the guidance of US/CT fusion in a room equipped with CT scanner. Feasibility of the procedure, accuracy of targeting, complications, and technique efficacy were evaluated.

Results

Of 227 patients treated from 2016 to March 2020, 91 patients (65 males and 26 females, mean age 68.5 ± 10.1 years) with 97 renal lesions (mean maximum diameter 21.6 ± 9.4 mm) inconspicuous/invisible (29/97, 29.9%) or poorly visible (68/97, 70.1%) at US underwent treatment under US-CT fusion guidance. US-CT fusion imaging guidance was always technically feasible and enabled correct targeting in 97/97/(100%) of cases. Technical success was achieved in 93/97 lesions (95.9%). Three lesions were retreated during the same ablative session, while 1 was retreated in a subsequent session. Thus, primary efficacy was achieved in one session in 96/97 (98.9%) cases and secondary efficacy in 97/97 (100%) cases

Conclusion

US-CT image fusion guidance allows for a correct tumor targeting of renal tumors poorly visible or inconspicuous/invisible with US alone, with a high rate of technical success and technique efficacy.

中文翻译：

---

实时US-CT融合成像指导超声消融治疗不可见或不可见的肾肿瘤：97例结果

摘要

目的

评估超声计算机断层扫描（US-CT）融合成像的能力，以指导精确靶向使用US可见或不可见的肾肿瘤

材料和方法

从2016年起，在我们的机构中​​，在配备CT扫描仪的房间内，在US / CT融合的指导下，对在美国可见或不明显/不可见的肾肿瘤进行了治疗。评估了该方法的可行性，靶向的准确性，并发症和技术功效。

结果

在2016年至2020年3月治疗的227例患者中，有91例肾脏病变（平均最大直径21.6±9.4毫米）不明显/看不见的患者（男65例，女26例，平均年龄68.5±10.1岁）（29/97，29.9％）或在US-CT融合指导下接受治疗的美国可见性较差（68/97，70.1％）。US-CT融合成像指南在技术上始终是可行的，并且能够在97/97 /（100％）的情况下正确定位。93/97个病灶（95.9％）取得了技术成功。在相同的消融期间，三处病变被治愈，而在随后的切除中，其中一处被治愈。因此，在96/97（98.9％）的病例中一次治疗达到了一次疗效，在97/97（100％）的情况中一次治疗达到了次要疗效

结论

US-CT图像融合指导可以仅使用US就能将肾肿瘤正确识别为不良可见或不显眼/不可见的肾肿瘤，并且具有很高的技术成功率和技术功效。